SK98793A3 - (s)-(+)-hydroxychloroquine - Google Patents

(s)-(+)-hydroxychloroquine Download PDF

Info

Publication number
SK98793A3
SK98793A3 SK987-93A SK98793A SK98793A3 SK 98793 A3 SK98793 A3 SK 98793A3 SK 98793 A SK98793 A SK 98793A SK 98793 A3 SK98793 A3 SK 98793A3
Authority
SK
Slovakia
Prior art keywords
hydroxychloroquine
substantially free
rheumatoid arthritis
pharmaceutically acceptable
malaria
Prior art date
Application number
SK987-93A
Other languages
English (en)
Slovak (sk)
Inventor
Vera J Stecher
William F Michne
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of SK98793A3 publication Critical patent/SK98793A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/46Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
SK987-93A 1992-09-15 1993-09-14 (s)-(+)-hydroxychloroquine SK98793A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/945,032 US5314894A (en) 1992-09-15 1992-09-15 (S)-(+)-hydroxychloroquine

Publications (1)

Publication Number Publication Date
SK98793A3 true SK98793A3 (en) 1994-09-07

Family

ID=25482508

Family Applications (1)

Application Number Title Priority Date Filing Date
SK987-93A SK98793A3 (en) 1992-09-15 1993-09-14 (s)-(+)-hydroxychloroquine

Country Status (18)

Country Link
US (1) US5314894A (de)
EP (1) EP0588430B1 (de)
JP (1) JPH06199801A (de)
KR (1) KR940007002A (de)
AT (1) ATE166646T1 (de)
AU (2) AU4732693A (de)
CA (1) CA2104903A1 (de)
CZ (1) CZ192393A3 (de)
DE (1) DE69318783D1 (de)
FI (1) FI934051L (de)
HU (1) HUT70025A (de)
IL (1) IL107004A0 (de)
MX (1) MX9305621A (de)
MY (1) MY109822A (de)
NO (1) NO180677C (de)
NZ (1) NZ248671A (de)
PH (1) PH30153A (de)
SK (1) SK98793A3 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453431A (en) * 1993-10-29 1995-09-26 Gilman; Andrew L. Use of hydroxychloroquine for treatment of graft-versus-host disease
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US20020198231A1 (en) * 1999-07-13 2002-12-26 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2005062723A2 (en) * 2003-11-24 2005-07-14 Ipca Laboratories Limited An improved process for the preparation of 7-chloro-4-(5-n-ehtyl-n-2-hydroxyethylamine)-2-pentyl] aminoquinoline and its intermediates
KR101115412B1 (ko) * 2008-09-08 2012-06-12 주식회사 대희화학 하이드록시클로로퀸의 신규 제조방법
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するc型肝炎ウイルス関連疾患の処置
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
EP2561868A1 (de) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmazeutische Zusammensetzungen mit Hydroxychlorocin (HCQ), Curcumin, Piperin/BioPerin und Verwendungen in der Medizin
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
CN105693606B (zh) * 2016-03-09 2017-12-05 西安科技大学 一种光学纯(r)/(s)‑羟氯喹的不对称合成方法
CN105693605B (zh) * 2016-03-09 2017-12-22 西安科技大学 一种光学纯(r)/(s)‑氯喹的不对称合成方法
CN110283121A (zh) * 2019-08-06 2019-09-27 华东理工大学 羟氯喹的合成方法
CN113350343A (zh) * 2020-03-06 2021-09-07 华南理工大学 右旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
CN113350344A (zh) * 2020-03-06 2021-09-07 华南理工大学 左旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
EP4135673A4 (de) * 2020-04-14 2024-05-08 Glanis Pharmaceuticals, Inc. System zur transdermalen und/oder topischen verabreichung mit hydroxychlorquin und/oder chloroquin
US20230139565A1 (en) * 2020-04-20 2023-05-04 Glanis Pharmaceuticals, Inc. Oral delivery system comprising hydroxychloroquine and/or chloroquine
TWI845802B (zh) * 2020-04-21 2024-06-21 健亞生物科技股份有限公司 硫酸羥氯喹之晶體
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
US20210369699A1 (en) 2020-05-31 2021-12-02 Genovate Biotechnology Co. Ltd. Treatment of lupus erythematosus using s-hydroxychloroquine
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111803501B (zh) * 2020-06-17 2022-10-18 南方科技大学 手性氯喹羟氯喹作为降低心脏毒性的用途
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯(深圳)科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112505198A (zh) * 2020-12-29 2021-03-16 珠海润都制药股份有限公司 一种s-硫酸羟氯喹异构体检验方法
CN117396204A (zh) * 2021-06-04 2024-01-12 健亚生物科技股份有限公司 使用s-羟氯喹治疗抗磷脂综合征
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN115089584A (zh) * 2022-06-14 2022-09-23 广州惠善医疗技术有限公司 手性羟氯喹或其药学上可接受的盐在制备防诊治免疫疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) * 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives

Also Published As

Publication number Publication date
JPH06199801A (ja) 1994-07-19
AU4732693A (en) 1994-03-24
NO180677B (no) 1997-02-17
EP0588430A1 (de) 1994-03-23
FI934051A7 (fi) 1994-03-16
MY109822A (en) 1997-08-30
PH30153A (en) 1997-01-21
NO933293L (no) 1994-03-16
HUT70025A (en) 1995-09-28
FI934051A0 (fi) 1993-09-15
NO180677C (no) 1997-05-28
KR940007002A (ko) 1994-04-26
HU9302613D0 (en) 1993-12-28
FI934051L (fi) 1994-03-16
US5314894A (en) 1994-05-24
NO933293D0 (no) 1993-09-15
CZ192393A3 (en) 1994-03-16
MX9305621A (es) 1994-03-31
ATE166646T1 (de) 1998-06-15
CA2104903A1 (en) 1994-03-16
IL107004A0 (en) 1993-12-28
NZ248671A (en) 1995-04-27
AU7549496A (en) 1997-04-10
EP0588430B1 (de) 1998-05-27
DE69318783D1 (de) 1998-07-02

Similar Documents

Publication Publication Date Title
SK98793A3 (en) (s)-(+)-hydroxychloroquine
DK172851B1 (da) Phenylcarbamater
US3466376A (en) Ortho - alkenylphenoxy - hydroxyalkyl derivatives in the treatment of cardiac and vascular diseases
DE69813896T2 (de) Alpha-aminoamidderivate die als analgetische mittel nützlich sind
JPH03294248A (ja) N−プロパルギル−1−アミノインダン化合物のr(+)−鏡像体、それらの製造法およびそれらを含有する薬剤組成物
SK167698A3 (en) Polymorphs of donepezil hydrochloride and process for production
JPH01500033A (ja) 置換2‐アミノテトラリン類
EP1373207A1 (de) Neues amlodipincamsylat und verfahren zu dessen herstellung
IE59941B1 (en) Piperidine derivative for treating pain
US6169094B1 (en) Compositions of (S) (-)-amisulpride
US4743618A (en) Substituted 2-aminotetralins
DE68907566T2 (de) Phenoxy- und phenylthio-, amino-substituierte Benzocyclo-alkan-Derivate bei der Behandlung und Verhütung von arzneimittelresistenten Protozoen-Infektionen.
CA2100158A1 (en) 3-hydroxypyridin-4-one derivatives as pharmaceutical compositions
AU568704B2 (en) Ether of n-propanolamine derivative
CN105924382B (zh) S-马尼地平盐酸盐i晶型及其制备方法
AU607437B2 (en) Resolution of dl-methyl 3-(4-(2-hydroxy-3-isopropylamino) propoxy)phenylpropionate((dl-esmolol))
HU211699A9 (hu) (S)-(+)-hidroxi-klorokvin Az átmeneti oltalom az 1-3. és 9-12. igénypontokra vonatkozik.
DE69619156T2 (de) Verwendung von alpha-Aminomethyl-3,4-dichlorbenzylthioaceamiden zur Herstellung eines dopaminwiederergreifungshemmenden Medikaments sowie Verbindungen zur Verwendung derselben
US4831049A (en) Pyrrolizidine compounds, and their use as antiarrhythmic agents
US3629418A (en) Process for producing an anti-depressant effect with piperazine quinolines
US6979740B2 (en) Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents
WO2013090319A2 (en) Treatment of type i and type ii diabetes
JP2004533418A (ja) 抗マラリア化合物
JPS6245525A (ja) 脂質低下剤
DE69621706T2 (de) Verwendung von Piperazinverbindungen als narkotische Antagonisten